174 results
Page 4 of 9
8-K
EX-99.1
zss0f0qm79yrq5gqw70d
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
umoe icdl
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-99.2
51p 2x9ruzv3i
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
tdcut ofm12khx6iof5z
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.1
zdhbkop
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
79qjn5323u02g
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
vp2pe ze2
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
S-8
8piskvi
10 Aug 20
Registration of securities for employees
4:16pm
8-K
EX-99.1
ftssao ksl4rqu91
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
og3898jj663 tmqkxcdq
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
EX-99.1
h116qea 0sa4uu0
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
EX-99.1
t6or iqevropiwquy
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
S-8
rtzzf
2 Mar 20
Registration of securities for employees
4:39pm